T-cell branched glycosylation as a mediator of colitis-associated colorectal cancer progression: a potential new risk biomarker in inflammatory bowel disease - Summary - MDSpire

T-cell branched glycosylation as a mediator of colitis-associated colorectal cancer progression: a potential new risk biomarker in inflammatory bowel disease

  • By

  • Eduarda Leite-Gomes

  • Mariana C Silva

  • Ana M Dias

  • Ângela Fernandes

  • Guilherme Faria

  • Rafaela Nogueira

  • Beatriz Santos-Pereira

  • Henrique Fernandes-Mendes

  • Catarina M Azevedo

  • Joana Raposo

  • Julian López Portero

  • Tania de Alda Catalá

  • Carlos Taxonera

  • Paula Lago

  • Maria J Fernandez-Aceñero

  • Isadora Rosa

  • Ricardo Marcos-Pinto

  • Salomé S Pinho

  • March 15, 2025

  • 0 min

Share

Objective:

To investigate the role of branched N-glycosylation in T cells as a mechanism influencing the development of colitis-associated colorectal cancer (CAC) and to identify it as a potential biomarker for inflammatory bowel disease (IBD) risk, emphasizing its clinical significance.

Key Findings:
  • Branched N-glycans in T cells increase from colitis to dysplasia and cancer stages, indicating a potential progression marker.
  • This glycosylation switch inhibits T cell function, impairing antitumor immune responses, which could inform therapeutic strategies.
  • Deletion of branched N-glycans in Mgat5 knockout mice leads to reduced CAC incidence due to enhanced CD8+ and γδ T cell infiltration, suggesting a protective mechanism.
  • Branched N-glycosylation levels in inflamed lesions predict CAC progression with 83.3% sensitivity and 67.9% specificity, highlighting its potential as a diagnostic tool.
Interpretation:

The study reveals a novel mechanism by which T-cell glycosylation influences the progression of CAC, suggesting that monitoring branched N-glycosylation could serve as a valuable biomarker for identifying high-risk IBD patients, with significant implications for clinical practice.

Limitations:
  • The study relies on specific cohorts, which may limit generalizability; further validation in larger, diverse populations is needed to confirm findings and address potential biases.
Conclusion:

The findings highlight the potential of T-cell glycosylation patterns as biomarkers for early detection of CAC in IBD patients, which could enhance cancer surveillance and preventive strategies, ultimately improving patient outcomes.

Original Source(s)

T-cell branched glycosylation as a mediator of colitis-associated colorectal cancer progression: a potential new risk biomarker in inflammatory bowel disease

  • by Eduarda Leite-Gomes, Mariana C Silva, Ana M Dias, Ângela Fernandes, Guilherme Faria, Rafaela Nogueira, Beatriz Santos-Pereira, Henrique Fernandes-Mendes, Catarina M Azevedo, Joana Raposo, Julian López Portero, Tania de Alda Catalá, Carlos Taxonera, Paula Lago, Maria J Fernandez-Aceñero, Isadora Rosa, Ricardo Marcos-Pinto, Salomé S Pinho

  • March 15, 2025

Related Content

Nitidine chloride suppresses polo-like kinase 1 via MYCN-associated transcriptional regulation in colorectal cancer: a multi-omics and spatial transcriptomics study

Case Report: Quantitative and qualitative evaluation for electroacupuncture combined with moxibustion in the treatment of recalcitrant low anterior resection syndrome

Development and validation of a pre-chemotherapy nomogram integrating systemic immune-inflammation index and prognostic nutritional index to predict severe adjuvant toxicity in colorectal cancer